Adaptimmune Therapeutics has priced its IPO at $17.50 per share, with the listing generating net proceeds of $191m.
GCP makes hybrid debt and equity investments of £5-30m across a variety of sectors
First investment made by the GP via Magnum Capital III, which was launched in December 2019
GP acquires a minority while the company's founders retain their majority ownership
Acon invests in partnership with Quarza Inversiones, which acquired a minority stake in the company